關於 Dendreon Corporation
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge, is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge.
Source: Wikipedia
總部Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
成立時間2013
狀態營運中
專利134 項專利
HUMORAL IMMUNE RESPONSE AGAINST TUMOR ANTIGENS AFTER TREATMENT WITH A CANCER ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY AND ITS ASSOCIATION WITH…CA2923433C · 2020
Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with…US10261091B2 · 2019
法律資訊
| 法定名稱 | Dendreon Corporation |
|---|---|
| LEI | 549300C0XK81HDI8KK82在 GLEIF 上查看 ↗ |
| 登記地址 | Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US |
| 狀態 | 營運中 |
來源: GLEIF · 更新於 2026年10月16日
聯絡方式與連結
地點
Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
這是你的公司嗎?
免費認領此頁面,即可新增標誌、產品、照片與職缺,並回覆評論。
認領此頁面